Sign in

NCT07433660Recruiting

WellSpan-THRIVE Cancer QOL Study

WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]

Source: ClinicalTrials.gov · Last updated 2 Mar 2026

Brief summary (registry, in English)

Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences. This study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
19 Feb 2026
Start date
Feb 2026
Primary completion date
Feb 2031
Lead sponsor
WellSpan Health
NCT number
NCT07433660

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From Feb 2026 to the primary completion date, Feb 2031
  • 5 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.
  • Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.

Age

  • Patients with age\<18 years,

Other

  • Patients with life expectancy of \<90 days, in the opinion of treating investigator.

Who the study is looking for

  • Age 18 years and above
  • Primary cancer diagnosis (newly diagnosed within the past 6 months)
  • Able to sign informed consent.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (5)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
WellSpan Medical Oncology & Hematology
Coordinator of this site? Confirm its status
ChambersburgUnited StatesRecruiting
WellSpan Ephrata Cancer Center
Coordinator of this site? Confirm its status
EphrataUnited StatesRecruiting
WellSpan Adams Cancer Center
Coordinator of this site? Confirm its status
GettysburgUnited StatesRecruiting
WellSpan Sechler Family Cancer Center
Coordinator of this site? Confirm its status
LebanonUnited StatesRecruiting
WellSpan York Cancer Center
Coordinator of this site? Confirm its status
YorkUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.